<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg"/></p>
<p>憑藉優化的 CAR 序列知識產權和細胞選擇性 LNP 技術，Liberate Bio 能夠推進體內 CAR-M 療法。圖片來源：sirtravelalot / Shutterstock.com。</p>
<p>Liberate Bio 已獲得與針對髓系細胞（如單核細胞和巨噬細胞）量身定製的嵌合抗原受體（CAR）設計相關的獨佔和非獨佔專利許可。</p>
<p>這些許可來自 Carisma Therapeutics 和賓夕法尼亞大學，包含專門為這些免疫細胞羣體的功能而設計的方法和構建體。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多發性骨髓瘤中的應用（Ka...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - Lisocabtagene Maraleucel 在慢性淋巴細胞白血病中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>這些設計補充了 Liberate Bio 的脂質納米顆粒（LNP）遞送平台，使其能夠在體內選擇性地編程巨噬細胞和單核細胞。</p>
<p>憑藉優化的 CAR 序列知識產權和細胞選擇性 LNP 技術，Liberate Bio 現在有能力將體內 CAR-M 療法推進到臨牀評估階段。</p>
<p>Liberate Bio 的 Raptor 平台在非人類靈長類動物中直接篩選 LNP，以發現針對肝外免疫細胞的遞送載體。</p>
<p>該公司之前披露，其領先的 LNP 通過選擇性編程單核細胞和巨噬細胞，導致非人類靈長類動物中循環 B 細胞的去除率超過 99%。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>Liberate Bio 的首席科學官 Walter Strapps 表示：“這項許可協議顯著增強了我們的臨牀項目。髓系細胞具有與 T 細胞不同的獨特生物學，優化其激活和持久性的 CAR 構建體至關重要。</p>
<p>“通過將經過驗證的 CAR 設計方法與我們的髓系選擇性 LNP 平台相結合，我們正在建立一種差異化且高度集成的體內細胞療法方法。”</p>
<p>Liberate Bio 首席執行官 Shawn Davis 表示：“體內 CAR-M 代表了免疫重編程的新篇章。通過將最佳遞送與優化的髓系 CAR 設計結合在一起，我們正在建立一個持久的基礎，以便為 CAR-T 提供可擴展且潛在更安全的替代方案——能夠覆蓋更廣泛的自身免疫和腫瘤指徵患者羣體。”</p>
<p>該公司計劃將其初始的體內 CAR-M 候選藥物推進到臨牀試驗（IND）啓用研究，目標是在 2026 年下半年通過研究者發起的試驗進行初步臨牀評估。</p>

生物科技 ETF - VanEck Vectors

IBBQ

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

CARM

動態生物技術與基因組 ETF - Invesco

<p>Liberate Bio 已獲得針對特定於髓系細胞的 CAR 設計專利的獨佔和非獨佔許可，增強其體內 CAR-M 療法。這些許可來自 Carisma Therapeutics 和賓夕法尼亞大學，包括針對單核細胞和巨噬細胞的工程化方法。該公司計劃在 2026 年底之前將其 CAR-M 候選藥物推進至臨牀試驗，利用其脂質納米顆粒技術進行靶向免疫細胞編程</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg"/></p>
<p>With optimised CAR-sequence intellectual property and cell-selective LNP technology, Liberate Bio can advance in vivo CAR-M therapies. Credit: sirtravelalot / Shutterstock.com.</p>
<div class="lb-trans"><p>憑藉優化的 CAR 序列知識產權和細胞選擇性 LNP 技術，Liberate Bio 能夠推進體內 CAR-M 療法。圖片來源：sirtravelalot / Shutterstock.com。</p>
</div><p>Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages.</p>
<div class="lb-trans"><p>Liberate Bio 已獲得與針對髓系細胞（如單核細胞和巨噬細胞）量身定製的嵌合抗原受體（CAR）設計相關的獨佔和非獨佔專利許可。</p>
</div><p>The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations.</p>
<div class="lb-trans"><p>這些許可來自 Carisma Therapeutics 和賓夕法尼亞大學，包含專門為這些免疫細胞羣體的功能而設計的方法和構建體。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多發性骨髓瘤中的應用（Ka...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Lisocabtagene Maraleucel in Chronic Lymphocyti...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Lisocabtagene Maraleucel 在慢性淋巴細胞白血病中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The designs complement Liberate Bio’s lipid nanoparticle (LNP) delivery platform, which enables the selective programming of macrophages and monocytes in vivo.</p>
<div class="lb-trans"><p>這些設計補充了 Liberate Bio 的脂質納米顆粒（LNP）遞送平台，使其能夠在體內選擇性地編程巨噬細胞和單核細胞。</p>
</div><p>With both the optimised CAR-sequence intellectual property and its cell-selective LNP technology, Liberate Bio is now positioned to advance in vivo CAR-M therapies into clinical assessment.</p>
<div class="lb-trans"><p>憑藉優化的 CAR 序列知識產權和細胞選擇性 LNP 技術，Liberate Bio 現在有能力將體內 CAR-M 療法推進到臨牀評估階段。</p>
</div><p>Liberate Bio’s Raptor platform conducts direct screening of LNPs in non-human primates to discover delivery vehicles aimed at extrahepatic immune cells.</p>
<div class="lb-trans"><p>Liberate Bio 的 Raptor 平台在非人類靈長類動物中直接篩選 LNP，以發現針對肝外免疫細胞的遞送載體。</p>
</div><p>The company has previously disclosed that its lead LNP resulted in more than 99% depletion of circulating B cells in non-human primates by selectively programming monocytes and macrophages.</p>
<div class="lb-trans"><p>該公司之前披露，其領先的 LNP 通過選擇性編程單核細胞和巨噬細胞，導致非人類靈長類動物中循環 B 細胞的去除率超過 99%。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>Liberate Bio’s chief scientific officer Walter Strapps said: “This licensing agreement meaningfully strengthens our clinical programmes. Myeloid cells have unique biology distinct from T cells, and CAR constructs optimised for their activation and persistence are essential.</p>
<div class="lb-trans"><p>Liberate Bio 的首席科學官 Walter Strapps 表示：“這項許可協議顯著增強了我們的臨牀項目。髓系細胞具有與 T 細胞不同的獨特生物學，優化其激活和持久性的 CAR 構建體至關重要。</p>
</div><p>“By combining validated methods for CAR designs with our myeloid-selective LNP platform, we are building a differentiated and highly integrated approach to in vivo cell therapy.”</p>
<div class="lb-trans"><p>“通過將經過驗證的 CAR 設計方法與我們的髓系選擇性 LNP 平台相結合，我們正在建立一種差異化且高度集成的體內細胞療法方法。”</p>
</div><p>Liberate Bio CEO Shawn Davis said: “In vivo CAR-M represents a new chapter in immune reprogramming. By uniting best-in-class delivery with optimised myeloid CAR designs, we are establishing a durable foundation for a scalable and potentially safer alternative to CAR-T — one capable of reaching broader patient populations across autoimmune and oncology indications.”</p>
<div class="lb-trans"><p>Liberate Bio 首席執行官 Shawn Davis 表示：“體內 CAR-M 代表了免疫重編程的新篇章。通過將最佳遞送與優化的髓系 CAR 設計結合在一起，我們正在建立一個持久的基礎，以便為 CAR-T 提供可擴展且潛在更安全的替代方案——能夠覆蓋更廣泛的自身免疫和腫瘤指徵患者羣體。”</p>
</div><p>The company intends to progress its initial in vivo CAR-M candidate into investigational new drug (IND)-enabling studies, targeting initial clinical evaluation via an investigator-initiated trial in the latter half of 2026.</p>
<div class="lb-trans"><p>該公司計劃將其初始的體內 CAR-M 候選藥物推進到臨牀試驗（IND）啓用研究，目標是在 2026 年下半年通過研究者發起的試驗進行初步臨牀評估。</p>
</div>

Liberate Bio 獲得了髓系特異性 CAR 設計專利的許可